Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Paraganglioma”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Study completedNCT01635907
What this trial is testing

Dovitinib in Neuroendocrine Tumors

Who this might be right for
Advanced Metastatic ParagangliomaAdvanced Metastatic PheochromocytomaRecurrent Paraganglioma+3 more
Abramson Cancer Center at Penn Medicine 8
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)UnknownNCT04029428
What this trial is testing

Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression

Who this might be right for
Neuroendocrine Tumors
University of Warmia and Mazury 150
Testing effectiveness (Phase 2)WithdrawnNCT04106843
What this trial is testing

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Who this might be right for
Locally Advanced Adrenal Gland PheochromocytomaLocally Advanced ParagangliomaMetastatic Adrenal Gland Pheochromocytoma+11 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT04394858
What this trial is testing

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Who this might be right for
Advanced Adrenal Gland PheochromocytomaAdvanced ParagangliomaMetastatic Adrenal Gland Pheochromocytoma+5 more
National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Study completedNCT02302833
What this trial is testing

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Who this might be right for
Locally Advanced ParagangliomaMetastatic Adrenal Gland PheochromocytomaMetastatic Paraganglioma+3 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT01413503
What this trial is testing

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Who this might be right for
PheochromocytomaParaganglioma
University of California, San Francisco 50
Testing effectiveness (Phase 2)Study completedNCT01967576
What this trial is testing

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Who this might be right for
PheochromocytomaParaganglioma
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03839498
What this trial is testing

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Who this might be right for
PheochromocytomaParaganglioma
Columbia University 6
Testing effectiveness (Phase 2)Looking for participantsNCT05636618
What this trial is testing

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+3 more
Perspective Therapeutics 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT02721732
What this trial is testing

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Who this might be right for
Advanced Malignant Solid NeoplasmCarcinoma of Unknown PrimaryMetastatic Adrenal Gland Pheochromocytoma+16 more
M.D. Anderson Cancer Center 157
Early research (Phase 1)Study completedNCT01155258
What this trial is testing

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Who this might be right for
Extensive Stage Small Cell Lung CancerHereditary ParagangliomaMale Breast Cancer+45 more
University of Southern California 19
Early research (Phase 1)Study completedNCT00005860
What this trial is testing

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00002608
What this trial is testing

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Who this might be right for
Adrenocortical CarcinomaBrain and Central Nervous System TumorsHead and Neck Cancer+4 more
Ottawa Regional Cancer Centre 30
Testing effectiveness (Phase 2)UnknownNCT05883085
What this trial is testing

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Who this might be right for
PheochromocytomaParaganglioma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT01152827
What this trial is testing

RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid

Who this might be right for
PheochromocytomaExtra-adrenal ParagangliomaNon-functioning Carcinoid
Seoul National University Hospital 33
Testing effectiveness (Phase 2)Study completedNCT00096083
What this trial is testing

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Who this might be right for
Cancer
Delcath Systems Inc. 56